REGISTERED CHARITY NUMBER: 1204969

REPORT OF THE TRUSTEES AND

UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

FOR

INTERNATIONAL SOCIETY OF HYPERTENSION

Advanta
Chartered Accountants
29 Gildredge Road
Eastbourne
East Sussex
BN21 4RU

INTERNATIONAL SOCIETY OF HYPERTENSION

CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

		Page
Report of the Trustees	TAR	1-14
Independent Examiner's Report		2
Statement of Financial Activities		3
Balance Sheet		4
Notes to the Financial Statements		5 to 11

Trustees' Annual Report for the period								
	Period start date			To	Period end date			
	Day	Month	Year		Day	Month	Year	
From	01	01	2025		31	12	2025	

Section A Reference and administration details

Charity name	**International Society of Hypertension**
Other names charity is known by	**ISH**
Registered charity number (if any)	**Registered charitable incorporated organisation (CIO) number 1204969.** Formerly ISH was an unincorporated charity with registered number1122135.
Charity's principal address	29 Gildredge Road Eastbourne East Sussex **Postcode** BN21 4RU

Names of the charity trustees who manage the charity

	Trustee name	Office (if any)	Dates acted if not for whole year	Name of person (or body) entitled to appoint trustee (if any)
1	Georgios (George) Stergiou (Greece)	President	01.01.25 – 31.12.25	
2	Jose Dagnovar Aristizabal-Ocampo (Colombia)		01.01.25 – 31.12.25	
3	Hind Mamoun Beheiry Ahmed (Sudan)		01.01.25 – 31.12.25	
4	Myeong-Chan Cho (South Korea)		01.01.25 – 31.12.25	
5	Débora Colombari (Brazil)		01.01.25 – 31.12.25	
6	Hiroshi Itoh (Japan)	Vice President	01.01.25 – 31.12.25	
7	Erika Jones (South Africa)	Officer at Large	01.01.25 – 31.12.25	
8	Kazuomi Kario (Japan	Secretary	01.01.25 – 31.12.25	
9	Tazeen Jafar (Singapore)		01.01.25 – 31.12.25	
10	Yan Li (China)		01.01.25 – 31.12.25	
11	Cesar Andres Romero (USA)	Treasurer	01.01.25 – 31.12.25	
12	Ulrike Steckelings (Denmark)		01.01.25 – 31.12.25	
13	Bryan Williams (UK)	Immediate Past President	01.01.25 – 31.12.25	

Names and addresses of advisers (Optional information)

Type of advisor	Name	Address
Accountant	Advanta Chartered Accountants	29 Gildredge Road, Eastbourne, East Sussex, BN21 4RU, UK

Name of chief executive or names of senior staff members (Optional information)

N/A

Section B Structure, governance and management

Description of the charity's trusts

Type of governing document

(eg. trust deed, constitution)	The current ISH Constitution was initially accepted by Society members on 26 September 2022. However, it was legally accepted on 29 September 2023, when ISH was officially registered as a Charitable Incorporated Organisation (CIO) in England and Wales (registration number 1204969).
How the charity is constituted (eg. trust, association, company)	The ISH is a registered Charitable Incorporated Organisation (CIO) in England and Wales (registration number 1204969) registered on 29 September 2023. The Society was previously an Unincorporated Charity (UC) registered under number 1122135. The transfer of all funds and net assets from the ISH UC to the ISH CIO was formally completed on 23rd December 2024. The Executive Committee of ISH concluded that transitioning from an UC to a CIO offered significant advantages to the Society. The most important benefits of the CIO structure to the ISH are: • Separate Legal Personality: The CIO has its own legal identity, allowing it to enter into contracts, own property, and conduct all business in the charity's name, rather than in the names of the individual Trustees. • Trustee Protection (Limited Liability): Members and Trustees are generally protected from personal liability for any debts or obligations incurred by the charity. This is a critical improvement, as Trustees of the previous UC were each and severally liable for the debts of ISH. The Trustees of the old charity and the CIO at the time of the transfer were the same persons. Accordingly, for most practical purposes the charity is continuing as before.
Trustee selection methods (eg. appointed by, elected by)	A call for nominations is made to membership. Votes are cast by Members at a General Meeting or by an electronic ballot. Those who are elected to membership of the ISH Council for the succeeding four years become Trustees and are formally appointed at the General Meeting.

Additional governance issues (Optional information)

You **may choose** to include additional information, where relevant, about: • Policies and procedures adopted for the induction and training of trustees. • The charity's organisational structure and any wider network with which the charity works. • Relationship with any related parties. • Trustees' consideration of major risks and the system and procedures to manage them.	ISH is a network committed to research and education for healthcare and allied professionals in the field of hypertension (high blood pressure) and on preventing its consequences, and for public information on hypertension. At the end of 2025, the ISH had an active membership of 3,329 members from all regions of the world, including key opinion leaders in hypertension, hypertension specialists, cardiologists, nephrologists, GPs, nurses, pharmacists, dietitians, scientists, community healthcare workers, and other healthcare professionals, all with a common interest in hypertension and related disorders from 135 countries, as well as 7 Corporate Member industry partners. The daily management of the ISH is undertaken by an Executive Committee (the Executive) on behalf of the Council, comprising of Officers of the Society: (President, Vice President, Secretary, Treasurer, Officer-at-Large and Immediate Past President), as well as an additional number of other elected Council Members as determined by the President. Committees and groupings have been established to assist with the management of the day-to-day activities of the Society. Each Committee is chaired by a member of the Council or by a Society member (a list of all the committees can be found on the Society website). Altogether, the members of ISH Executive, the Council and all the members of ISH Committees constitute

the ISH leadership.

ISH administrative support for membership, communications, finance and other identified areas including industry engagement is maintained by external service providers. The Society has one ISH employee with key responsibilities to support the Executive, Council, and the ISH leadership. The aim is for this dedicated full-time support to help the Society and volunteers and maintain continuity with activities.

As the Society does not undertake fundraising from the general public, the major risks to the continuation of the Society's programme of educational activities are from a decrease in income from its industry partners, reduction in revenue from the *Journal of Hypertension* annual royalty fee and from its Scientific Meetings. Traditional and social media marketing and publicity is used to attract attendance to the ISH Scientific Meetings. Amounts spent to achieve the Society Objects of education are limited by the income received (see under 'Reserves Policy' in section E, below).

Section C Objectives and activities

Summary of the objects of the charity set out in its governing document

To protect and promote the health of the public in particular by encouraging the advancement of scientific research and knowledge and of its application in all aspects of hypertension and associated cardiovascular diseases and to disseminate the useful results of such research.

Summary of the main activities undertaken for the public benefit in relation to these objects (include within this section the statutory declaration that trustees have had regard to the guidance issued by the Charity Commission on public benefit)

Education:
ISH primarily works with affiliated societies in the regions (via its six Regional Advisory Groups) to forge stronger links with national and regional societies of hypertension and related bodies, to create wider awareness of the Society and importantly, to offer support and help educate those in countries and regions most in need.

The ISH Regional Advisory Groups (RAGs) ensure that the Society is listening and responding to all members of its international constituency with a local flavour. Since October 2020, the map of ISH RAGs has been aligned with six World Health Organization (WHO) regions; there are RAGs in ISH as follows:

1. Africa
2. Americas
3. Asia Pacific (APAC)
4. Europe
5. Middle East and North America (MENA)
6. South and Central Asia (SACA)

These groups are intended to provide comprehensive Society representation globally, to distil regional issues, encourage and enhance education and biomedical research in the fields of hypertension and associated cardiovascular diseases, support the emergence of new regional and national societies, work with existing societies to undertake joint projects in the propagation of hypertension prevention and facilitate closer working relationships and collaboration between overlapping regional groups.

Scientific Meetings:
The ISH Scientific Meetings are a platform for presenting completed and original scientific investigations and where delegates from all over the world can meet and discuss public health, clinical and population aspects of hypertension research.

An important decision was made by the ISH Council in 2025 to hold annual scientific meetings from 2026. The shift to annual meetings replaces the current schedule – established in 1970 – of holding a meeting every two years. The move reflects the ISH's commitment to providing more frequent opportunities for scientific exchange and collaboration. It will also enable the

Society to have a presence in more regions of the world, more often.

See section D for further information on plans that are underway for the 2026, 2027 and 2028 events.

Capacity Building Network
The ISH Capacity Building Network (CBN) offers career development and networking opportunities for early and mid-career researchers and those from under-represented backgrounds. The Network is a collaboration between three ISH committees: the Women in Hypertension Research Committee (WiHRC), the New Investigator Committee (NIC), and the Mentorship and Training Committee (MTC) and lead by the chairs of these committees.

Established in November 2023, the Capacity Building Network (CBN) is dedicated to empowering investigators with essential research skills. Through a comprehensive suite of webinars, workshops, podcasts, and digital resources, the CBN supports career progression for researchers worldwide.

New Investigator and Mentorship and Training Committees:
It has been the mission of the ISH to encourage and support younger researchers, as the next generation of leaders in the global management of blood pressure. Through the continued development of the New Investigator and Mentorship and Training Committees and the related New Investigator Network and mentorship webpages (https://ish-world.com/new-investigators / https://ish-world.com/mentorship), and presence on social media platforms (Facebook, X, Instagram, YouTube and LinkedIn), the Society is extending its reach to the new generation of researchers and doctors and future leaders in the field.

Women in Hypertension Research Network:
The ISH Women in Hypertension Research Network was established in 2016 to encourage, support and inspire women in science and medicine in the field of hypertension and related cardiovascular diseases. It aims to allow new avenues for communication, collaboration and education. The key aims are:

- To promote women scientists and clinicians so that they can fulfil their career aspirations in the field of hypertension and related cardiovascular diseases.
- Provide a platform for networking and mentoring to enable women hypertension researchers to maximise career opportunities. In particular, to reach out to those who do not have formal mentoring support.
- Recognise and promote the successes of women in the hypertension community.
- Involve all ISH members in promoting equal opportunities for women in science and medicine based on merit.

Affiliated Society and Partner Collaborations:
Increasingly effective links have been forged amongst national and regional societies of hypertension and related comorbidities and high blood pressure research councils around the world. Via our six Regional Advisory Groups ISH has continued to provide a platform for research and intellectual exchange of ideas pertinent to scientific, economic and ethical aspects of cardiovascular prevention and care.

The ISH RAGs additionally help to provide comprehensive Society representation globally, to resolve regional issues and encourage and enhance education and biomedical research in the fields of hypertension and associated cardiovascular diseases.

Public Awareness:

World Hypertension Day (17 May):
Raised blood pressure is the biggest single contributing risk factor for global death. Lots more needs to be done by governments, public health agencies and healthcare systems to counter the devastating and perpetual menace of hypertension – the silent killer. As a result of the rapidly growing burden of disease associated with the global increase in hypertension the Society supports and encourages involvement in the annual World Hypertension Day on 17

May by Society members and affiliated regional and national societies (established by our partner organisation World Hypertension League).

The theme of WHD in 2025 was 'Measure your blood pressure accurately, control it, live longer' focusing on combatting low awareness rates worldwide, especially in low-and middle-income areas, and accurate blood pressure measurement methods.

As a part of commitment to awareness of high blood pressure, on 17 May 2025 the Society released a short video from the President to encourage our members and the wider hypertension community to help raise awareness of the importance of knowing your blood pressure and understanding what to do if it is high. Furthermore, the Society curated and shared a resource page to mark WHD, to highlight fantastic global activities taking place by many of our Affiliated Societies and members, as well as to share a series of ISH graphics to highlight the need for greater focus on high blood pressure and the dangers of hypertension. Some of the graphics (which could also have been printed as posters) are aimed at healthcare professionals and some are aimed at members of the public. Our materials were translated into other languages and used around the world.

Work was carried out in 2025 to finalise the ISH Patient-focused guideline designed to empower and talk to patients. This patient-focused guideline will provide people worldwide with the essential tools and knowledge required to effectively detect, monitor, and control their blood pressure.

World Adherence Day
With partner organisations (including the World Heart Federation), the ISH marked World Adherence Day. This is an initiative aimed at raising awareness about the importance of sticking to prescribed healthcare plans. The day emphasised the significance of adherence to treatments, especially for chronic conditions, to improve health outcomes and reduce complications.

The campaign encourages individuals to follow their healthcare providers' recommendations, whether it involves medication, lifestyle changes, or maintaining a healthy routine. The theme for the day in 2025 was Don't Miss a Moment, highlighting the importance of staying on track with healthcare plans to protect meaningful moments in life.

Our promotional activities involved materials publicised via our website, social media channels, our publication Hypertension News and through our monthly bulletin.

May Measurement Month:
Building on the success of the existing WHD, the ISH designated the entire month of May as May Measurement Month (MMM) in 2017. The aim was to highlight the importance of measuring your blood pressure (BP) and to raise awareness of the dangers posed by elevated BP and hypertension. The target is to increase the numbers of participants aged 18+ who are regularly getting their BP checked and to give people the tools to understand how this information can contribute to a person's knowledge about their individual health. MMM also provides diet and lifestyle advice to those with BP in the hypertensive range and to facilitate improved follow up for sufferers.

The ISH leadership introduced a new model of governance for the MMM initiative, which became effective from 1st January 2022. This is because the expansion of MMM was increasingly consuming leadership time and resources from the ISH, distracting from the opportunity to launch new initiatives. In this new arrangement, MMM has become an independent charity in England and Wales. However, the campaign continues to remain strongly affiliated with the ISH as the founding partner and successful MMM activities took place once again in many parts of the world in 2025, with input from numerous ISH members and members of the ISH leadership.

Public Benefit
The Trustees have read the guidance issued by the Charity Commission relating to public benefit and can confirm that the above activities of the ISH benefit the public in general. This is

achieved by improving the depth and spread of knowledge in the field of hypertension and cardiovascular disease, fostering the translation of novel clinical research and basic science into best clinical practice and increasing public awareness of raised blood pressure. Upskilling practitioners improves healthcare for all those with hypertension and other related diseases. The charity has a track record of organising high-quality educational courses, seminars, and meetings all over the world, as well as providing expert faculty members to disseminate the latest hypertension management guidelines. All these activities result in increased knowledge by clinicians treating hypertension. There are no restrictions to this overall benefit in healthcare, as specified in the Charity Commission guidance (e.g., in terms of access, geography, membership, ability to pay etc).

Section D Achievements and performance

Summary of the main achievements of the charity during the year

Achievements and Performance

SOCIETY MEMBERSHIP:

The Society has a dedicated Membership Committee to:

(1) actively recruit new members
(2) attract more geographically comprehensive membership and expand ISH's global footprint of members
(3) retain members and encourage active participation
(4) increase the number of paying members

Members in 2025 included trainees, junior and key opinion leaders in hypertension, hypertension specialists, cardiologists, nephrologists, GPs, nurses, pharmacists, dietitians, scientists, community healthcare workers, and other healthcare professionals, all with a common interest in hypertension and related disorders

At the end of 2025, the Society had 3,329 members constituting 647 full Members (including ISH Fellows (ISHFs), Distinguished, Emeritus and Honorary Fellows), 163 Trainees and 2,519 Associate Members. In addition, there were 5 Corporate Members (organisation - industry partners).

The ten countries with the highest number of members included India, Pakistan, USA, Nigeria, Japan, China, Australia, Argentina, Italy and UK.

The ISH continued to work with a membership management organisation based in Argentina in 2025 to improve the interface with ISH members. Working in Latin America is allowing the Society to open our doors to the large Spanish speaking hypertension community that had previously been untapped by the ISH.

Achievements in 2025:

- Our global footprint expanded significantly, reaching a membership base that spans all regions of the world (in approximately 135 countries).
- Reduced fees for members from parts of the world where fees can be a barrier to membership.
- Extensive promotion of the two free membership categories (Associate Member and Trainee) at various events globally and on social media.
- Membership portal updated on a regular basis to offer members access to training, resources, and other member benefits.
- A much-reduced cost subscription to the ISH's official Journal – the *Journal of Hypertension* – continued to be offered to members via the membership portal.

ISH SCIENTIFIC MEETINGS:

ISH 2026 Scientific Meeting

Dubai was selected as the destination for the ISH 2026 meeting in 2023. The co-host of this meeting will be the Emirates Cardiac Society. Planning continued for this event in 2025 following the official launch at the end of the ISH Cartagena September 2024 meeting.

ISH 2028 Scientific Meeting
At the end of 2024, the ISH and European Society of Hypertension (ESH) leadership signed an agreement to hold a joint meeting in 2028 in Europe, in the tradition of several successful joint meetings in the past, with proposals to host the meeting invited in 2025.

ISH Annual Scientific Meetings from 2026
A decision was made by the ISH Council in November 2025 to significantly accelerate scientific progress and knowledge dissemination in the field of hypertension and to commit to holding its ISH Scientific Meeting annually, starting in 2026.

Bids to host the meeting were invited in December 2025 to host the ISH 2027 Meeting, with a view to a destination decision being made early 2026.

SOCIETY'S JOURNAL, PUBLISHED PAPERS AND STATEMENTS:

In 2025, the ISH continued to partner with the *Journal of Hypertension,* as the official journal of the Society. In addition to primary papers from world-renowned experts, the Journal (published by Wolters Kluwer) contains authoritative reviews that summarise and evaluate the most significant recent developments. Further self-published items include *ISH Hypertension News* (a magazine produced approximately 3 times per year) read by the Society's more than 8,000 Members and subscribers and the *ISH monthly e-Bulletin*.

Papers published in 2025 by the ISH or with ISH leadership authorship included the following.

Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline
J Clin Endocrinol Metab. 2025 Aug 7;110(9):2453-2495. doi: 10.1210/clinem/dgaf284.
The ISH was proud to announce its formal endorsement and co-sponsorship of the 2025 Endocrine Society clinical practice guideline. This high-impact publication represents a vital step forward in aligning international standards for the diagnosis and management of this critical condition, underscoring ISH's commitment to bridging endocrine and cardiovascular expertise to improve patient outcomes globally. The Guideline was developed with significant contribution of Past ISH Council Member and co-author Nadia Khan.

The ISH Research and Education Committee continued work in 2025 in the development of multiple new position papers for publication in 2026 including key topics including paediatric hypertension and hypertension in pregnancy. Authorship of the papers will include representation from Society leadership and membership in all regions where possible, including a high percentage of women and new investigators as collaborators.

ENDORSED EVENTS AND PAPERS:

The ISH, as a respected body of expertise, is frequently asked to endorse events and publications. It assesses these requests on the basis of criteria which are published on its website. The ISH Research, Science and Education Committee and Council typically consider several such requests each month. A sample of the successful requests follows.

- An initiative to improve hypertension care in Thailand held in Bangkok in March. The Hypertension Camp from the Thai Hypertension Society (THS) helps equip healthcare workers to become champions in hypertension care in the hospitals where they work.
- The book *"Cracking the Code of Medication Non-Adherence"* was developed in conjunction with Abbott's a:care initiative. The text advocates for a paradigm shift toward patient-centered care and acknowledges the ISH's vital role in advancing global medication adherence.

- The Servier "EVIDENT Summit" on cardiometabolic disease held in Dubai, UAE. Past President Alta Schutte participated in the event held to address the critical challenge of treatment inertia.

REGIONAL EDUCATIONAL AND TEACHING ACTIVITIES:

To forge stronger links with national and regional societies of hypertension and related bodies, create wider awareness of the Society and to continue to disseminate information regarding the *2020 ISH Global Hypertension Practice Guidelines*, the ISH works - mainly via its six Regional Advisory Groups (RAGs) - with affiliated societies and sends Teaching Faculty, Council members or other members of the ISH leadership to participate in, and offer educational content at, numerous global activities each year.

ISH representatives presented at, and held joint sessions, at a great number of educational and teaching activities and meetings in 2025 including:

AFRICA

- September: Pan African Society of Cardiology (PASCAR). The ISH Africa Regional Advisory Group chair Alfred Doku presented the plenary address on the development of new unified hypertension guidelines for hypertension in Africa. To add to this, the ISH promoted Society membership at a dedicated booth.

AMERICAS

- April: Argentine Society of Hypertension (SAHA). ISH supported the new investigator awards presented on this occasion.
- July: Brazilian Society of Hypertension. ISH supported a Speed Networking and Mentoring 'Let's talk about your career' Session
- August: The ISH was supported at a one-day symposium in Buenos Aires, entitled 'Bridging the Generations in Science'. This targeted early career researchers.
- September: Peruvian Society of Arterial Hypertension. ISH President George Stergiou gave the keynote lecture.
- September: A webinar from the ISH Americas Regional Advisory Group and the Colombian Society of Cardiology and Cardiovascular Surgery (SCCCV) was held on how to translate the recommendations of the latest American Heart Association 2025 and European Society of Cardiology 2024 guidelines for hypertension into practice.

APAC

- February: Indonesian Society of Hypertension (InaSH). ISH President George Stergiou made two presentations in key meeting sessions.
- May: Malaysian Society of Hypertension (MSH)
- July: Pulse of Asia (POA) held in Shanghai. ISH Council member Yan Li (POA) organising committee lead) represented the Society.
- July: A joint summer school from the China Hypertension League (CHL), the European Society of Hypertension (ESH) and ISH took place in the city of Xining, China.
- October: Japanese Society of Hypertension (JSH)
- October/November: Chinese Hypertension League (CHL)
- November: Vietnamese Society of Hypertension (VSH)
- November: Korean Society of Hypertension (KSH). Speakers included the ISH Treasurer Cesar Romero.
- November: 20th Asian-Pacific Congress of Hypertension 2025 (APCH-2025) and Indian Society of Hypertension BPCON- 2025
- December: Hypertension Australia

EUROPE

- May: European Society of Hypertension (ESH) Meeting /Joint ISH-ESH Session
- August: European Society of Cardiology (ESC) / Joint ISH-ESC Session

- November: Hellenic Society of Hypertension. Representation by the ISH President.
- November: 11th International Conference on Prehypertension, hypertension and the cardio metabolic syndrome / 6th Croatian Congress on Hypertension / 15th Croatian Congress on Atherosclerosis. Representation by the ISH President and members of the Europe Regional Advisory Group.
- December: French Society of Hypertension.

MENA

- October: Emirates Cardiac Society
- November: Saudi International Hypertension Conference

SACA

- March: 6th World Hypertension Congress, with the World Hypertension League, India
- June: Sri Lanka Hypertension Society
- September: Pakistan Hypertension League (PHL) Meeting. The event featured an ISH South and Central Asia- PHL joint session 'Hypertension Without Borders: Collaborative Action for South and Central Asia'. An ISH dedicated booth was used to promote Society membership.

ONLINE COURSES, EVENTS AND OTHER EDUCATIONAL ACTIVITIES:

- The ISH Africa RAG reached the final stages of developing a simplified, unified African guideline in 2025 in collaboration with the Pan African Cardiology Society (PASCAR). Derived from the ISH 2020 standards and regional evidence, the guideline is scheduled for publication in 2026.

- Two ISH Collaboration Exchange Scholarships were awarded at the start of 2025. The scholarships, each worth USD 5,000, were awarded to support the development of international collaborations which began at the 2024 ISH Scientific Meeting.

- The ISH in collaboration with the Hypertension Core Group of *IAPEN India Association of Parenteral and Enteral Nutrition* organised a special webinar series to mark World Heart Day on 29th September 2025. The series of four webinars was conducted from 28th to 30th September and Society involvement was via the ISH South and Central Asia (SACA) Regional Advisory Group (RAG). Four members of the ISH SACA RAG spoke at a webinar focused on the theme of lifestyle and hypertension - challenges and solutions for low and middle-income countries.

- ISH continued to endorse the Certificate Hypertension Programme in Spanish organised by the Argentine Society of Hypertension (SAHA) and with significant support given from the ISH Americas RAG.

The Society additionally worked with the following global organisations and hypertension related societies to support the following activities:

- STRIDE BP e-learning platform: STRIDE BP is an international scientific non-profit organization that provides guidance on the methodology and technology for accurate blood pressure evaluation. It is officially supported by the *ISH*, the *European Society of Hypertension*, and the *World Hypertension League*. https://www.stridebp.org/

- Global Coalition for Circulatory Health (GCCH): GCCH brings together 32 international, regional and national stakeholders in circulatory health to drive the urgent action needed to combat heart disease and stroke. Their efforts include publishing position papers and white papers.

- OMRON Academy: ISH continued to support Omron Healthcare with their online curriculum on hypertension. OMRON Academy is a curriculum framework made by

expert scientists and offers continuous medical education for healthcare professionals. The training highlights specific challenges in the field of hypertension and respiratory disease and offers updates on the latest advances in these fields. The online courses are developed for mobile and desktop use, and the hypertension courses are endorsed by the ISH, European Society of Hypertension (ESH) and the British and Irish Hypertension Society (BIHS). After completing each module, participants receive a certificate of completion which can be used for continuing medical education (CME) credits.

Looking forward to 2026:

Plans were advanced in 2025 to launch an ISH specialised educational platform called ISH Academy.

The Academy ISH educational platform is in the process of being established to provide standardised, high-quality content for ISH members. This will offer a go to place for the hypertension community, and educational platform will discuss various aspects of hypertension. The aim is for accreditation to be offered so those completing the process will be recognised by their peers. The course will offer a curriculum and not just a series of presentations and be updated on an ongoing basis to keep this current.

NEW INVESTIGATOR, MENTORSHIP AND WOMEN IN HYPERTENSION RESEARCH COMMITTEE ACTIVITIES:

Capacity Building Network
The ISH Capacity Building Network (CBN) was launched in 2023 to offer career development and networking opportunities for early and mid-career researchers and those from under-represented backgrounds. The collaboration continues to strengthen the activities of the Society.

In 2025, the network hosted a series of high-impact webinars including those on the following key topics:

- Paths to Scientific Independence
- The Pressure is On: Navigating Career Challenges as Women in Hypertension Research.

New investigator Committee (NIC)
The Society continued to encourage interaction and involvement with the ISH New Investigator Network on the Society website and via social media platforms, Facebook, X and LinkedIn. The Society circulated regular news via the main Society news channels to focus on the achievements of new researchers or clinical scientists undertaking a higher degree. To add to this, the spotlight section was retained on the Society webpages to feature hypertension future leaders.

Mentorship and Training Committee (MTC)
The focus of the Mentorship and Training Committee in 2025 was to continue the successful ISH Mentorship Scheme. This is an exciting scheme designed to bring together new investigators (students and hypertension researchers who are within 10 years of a doctoral degree) and more experienced investigators.

Following the ISH 2024 Scientific Meeting, the Committee launched 'Global Career Journeys.' This video series explores the diverse professional paths of our members and highlights the transformative impact of ISH mentorship across the globe.

Women in Hypertension Research Committee (WiHRC)
The long-term goal of the Women in Hypertension Research Committee (WiHRC) is to address the barriers to progression that affect women and other under-represented groups within the society and to ensure equality of opportunity for all across the Society's activities and within

the wider hypertension research community.

The spotlight section was retained on the Society webpages to provide an international platform to promote outstanding women working in hypertension research, learn about their scientific interests/achievements and to tell their personal story.

COMMUNICATION / WEBSITE:

Extensive efforts were made in 2025 to increase the level and content of communication from the ISH to Society members and those non-ISH members engaged within the hypertension community. The ISH magazine - *Hypertension News* - continued to be sent to stakeholders and made available on the ISH website. It is focused on scientific content and major updates and remains highly readable. Our members regularly express interest in communicating and exchanging their ideas via this publication. There were three issues in 2025. In addition, the monthly *e-Bulletin* for membership was expanded to match the increased activity within the Society and increased recognition of partner activity. Our magazine and bulletin are highly valued, with open rates for our email bulletins around 40-50%.

The Communications team extensively promoted the ISH 2026 Dubai meeting via a mixture of traditional (e-mail, Hypertension News, E-bulletin) and social media (Twitter, Facebook, YouTube, LinkedIn). All efforts were made and coordinated with the local organising committee (Emirates Cardiac Society).

Other key activities in 2025 included extensive promotion of Society membership.

In 2025 the ISH continued to develop its website to provide easier navigation and a higher quality browsing experience for our members and visitors.

The ISH is also keeping up to date on modern communication practices, employing use of video, and new social media platforms. For example, the Society is now on Instagram and BlueSky. This extends the reach and visibility of our charitable activities.

We also use our comms platforms as a way of promoting the work and activities of our affiliated national and regional societies around the world.

PARTNERSHIPS:

Additional new and ongoing partnerships were established and maintained with the following organisations – apart from the ongoing relationship that the Society has with over 80 national hypertension and cardiac societies globally.

European Society of Hypertension (ESH), Asian Pacific Society of Hypertension (APSH), Latin-American Society of Hypertension, Endocrine Society, Resolve to Save Lives, KDIGO BP measurements standardization consensus partnership, *Cardiovascular Research*, World Health Organization (WHO), Framework Convention Alliance for Tobacco Control, International Alliance of Patients' Organizations, International Council of Nurses, International Diabetes Federation, International Society of Nephrology, World Federation of Public Health Associations, World Heart Federation, World Hypertension League (WHL), World Organization of Family Doctors, World Stroke Organization, and International Atherosclerosis Society via the Global Coalition for Circulatory Health (GCCH) and HEARTS Initiative led by the WHO.

ISH GUIDELINES IMPLEMENTATION INITIATIVE

Work commenced late 2025 on the Guidelines Implementation Initiative. This is a new framework designed by the Society to translate clinical theory into effective frontline practice. The programme aims to improve global blood pressure control through three core pillars:

Section D Achievements and performance

- Regular Updates: Keeping the Global Hypertension Practice Guidelines current.
- Digital Innovation: Developing "ISH OnTheGo," an AI-powered tool to assist clinicians in real-time.
- Global Outreach: A strategic implementation and dissemination plan led by a dedicated committee to ensure worldwide awareness and adoption.

INDUSTRY

Recognising the need for robust stakeholder management, the ISH invested in a dedicated resource in 2025. This strategic move aims to deepen relationships with our Corporate Members, sponsors of our Scientific Meetings and other funding activities. By providing a consistent interface for our industry partners, the ISH is better positioned to secure the diversified funding necessary to drive our global initiatives forward.

Section E Financial review

Brief statement of the charity's policy on reserves

The financial position of the Society is considered by the Trustees to be in good order as shown by the financial statements.

As the Society does not undertake fundraising from the general public and in view of the uncertainty of long-term support from the Scientific Meetings and Corporate Members, the Trustees have approved a strategy to maintain the balance of the accounts to a reasonable sum of at least ~£500,000 to guarantee sustainable charitable activities in the event of unfavourable financial circumstances.

The Society also wishes to continue its policy of holding Scientific Meetings in regions of the world which on occasion, may not attract as much sponsorship as others and it is therefore important to maintain sufficient reserves as indicated above to ensure existing commitments are met in the event that the Scientific Meetings do not make a significant surplus. This was notably the case for the Colombia 2024 Scientific Meeting which was the first ISH meeting held in Latin America since 2004 and an invaluable opportunity to better connect with the community in the region and expand the reach of the Society.

Financial Overview for 2025

- Total income for the year amounted to £226,467, representing a decrease of £91,541 compared to 2024 (£318,008).
- Direct charitable expenditure in 2025 totalled £340,366, which includes foreign exchange losses of £23,905. Charitable expenditure in 2024 totalled £334,904 Expenditure exceeded income by £113,899, resulting in a net reduction in funds for the Society.
- This resulted in a total funds balance of £797,156 as of 31 December 2025, compared to £911,055 in 2024

New charitable expenditures have been committed for 2026, including further educational activities in the regions.

It is also the aim of the Society to further build its research activities, and it is therefore important to have sufficient reserves to honour these longer-term research commitments.

Further financial review details (Optional information)

You **may choose** to include additional information, where relevant about:

- The charity's principal sources of funds (including any fundraising).
- How expenditure has supported the key objectives of the charity.
- Investment policy and objectives including any ethical investment policy adopted.

The Society's programme of educational activities is funded primarily in four ways:

1. Royalties: The Society receives a small percentage of the revenue made by the *Journal of Hypertension*, the Society's official journal.

2. Corporate Members: The contributions made by approximately 7 commercial companies enable the Society to continue to develop existing initiatives and provide new educational resources and activities. Donations from our industrial partners are received on the condition that all activities undertaken by the Society are managed by the Trustees alone, and that the Corporate Members are not involved with any decision-making.

3. Project and endorsement support: Industry contributes project and endorsement support either to acknowledge ISH's endorsement or to facilitate specific Society initiatives.

4. Scientific Meetings: The Society receives a percentage of any surplus from these conferences. This amount can vary considerably each time, depending on how much income is received from sponsorship and registration fees.

5. Membership subscription fees.

Our overarching investment objective is to achieve a combination of sustainable growth and income. We aim to generate returns that allow us to fulfil our charitable purposes while carefully preserving the capital value of our portfolio. To manage liquidity and earn a return on short-term funds, a portion of our cash balances will be held on interest-bearing deposit.

RESPONSIBILITIES OF THE TRUSTEES FOR THE FINANCIAL STATEMENTS

The Trustees are responsible for preparing the report of the Trustees' and the financial statements in accordance with applicable law and regulations.

The Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charity of the incoming resources and application of resources, including the income and expenditure, of the charity for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgments and estimates that are reasonable and prudent;
- state whether applicable UK accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.


The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charity's transactions, disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the provisions of the charity's Constitution. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Section F Other optional information

Not applicable

Section G Declaration

The trustees declare that they have approved the trustees' report above.
Signed on behalf of the charity's trustees

Signature(s)		
Full name(s)	Professor George Stergiou	
Position (eg secretary, chair)	President	

Date 16th October 2026

REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2025

The trustees present their report with the financial statements of the charity for the year ended 31 December 2025. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity is governed by its constitution, and is a Charitable Incorporated Organisation (CIO).

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Charity number

1204969

Principal address

c/o Advanta Chartered Accountants
29 Gildredge Road
Eastbourne
BN21 4RU

Trustees

Dr H Itoh
Dr G Stergiou
Professor M Cho
Professor U M Steckelings
Professor B Williams
Professor T Jafar
Ass Prfssr C A Romero
Professor K K Kario
Professor E S W Jones
Professor H Beheiry
Professor D Colombari
Professor J Aristizabal-Ocampo
Professor Y Li

Independent Examiner

Mr T Durrant
Advanta
Chartered Accountants
29 Gildredge Road
Eastbourne
East Sussex
BN21 4RU

The detailed trustees report is set out on pages TAR 1 to 14.

Independent examiner's report to the trustees of International Society of Hypertension
I report to the charity trustees on my examination of the accounts of International Society of Hypertension (the CIO) for the year ended 31 December 2025.

This report is made solely to the trustees as a body, in accordance with the Charities Act 2011. My examination has been undertaken so that I might state to the trustees those matters I am required to state to them in an independent examiner's report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the charity and the trustees as a body, for my examination, for this report, or for the opinions I have formed.

Responsibilities and basis of report
As the charity trustees of the CIO you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the Act').

I report in respect of my examination of the CIO's accounts carried out under Section 145 of the Act and in carrying out my examination I have followed all applicable Directions given by the Charity Commission under Section 145(5)(b) of the Act.

Independent examiner's statement
I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the CIO as required by Section 130 of the Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Mr T Durrant

Advanta
Chartered Accountants
29 Gildredge Road
Eastbourne
East Sussex
BN21 4RU

Date: 20 October 2026

INTERNATIONAL SOCIETY OF HYPERTENSION

STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 DECEMBER 2025

	Notes	Unrestricted fund £	Restricted fund £	2025 Total funds £	2024 Total funds £
INCOME AND ENDOWMENTS FROM					
Donations and legacies		-	-	-	1,162
Other trading activities	3	218,044	-	218,044	312,001
Investment income	4	8,423	-	8,423	4,845
Total		226,467	-	226,467	318,008
EXPENDITURE ON					
Raising funds	5	189,289	3,263	192,552	171,340
Charitable activities	6				
Charitable activities		123,693	24,121	147,814	163,563
Total		312,982	27,384	340,366	334,903
NET INCOME/(EXPENDITURE)		(86,515)	(27,384)	(113,899)	(16,895)
RECONCILIATION OF FUNDS					
Total funds brought forward		868,296	42,759	911,055	927,950
TOTAL FUNDS CARRIED FORWARD		781,781	15,375	797,156	911,055

CONTINUING OPERATIONS
All income and expenditure has arisen from continuing activities.

Comparative figures are a combination of the old charity and the CIO.

The notes form part of these financial statements

INTERNATIONAL SOCIETY OF HYPERTENSION

BALANCE SHEET
31 DECEMBER 2025

	Notes	Unrestricted fund £	Restricted fund £	2025 Total funds £	2024 Total funds £
FIXED ASSETS					
Tangible assets	12	1,098	-	1,098	2,198
CURRENT ASSETS					
Debtors	13	137,398	-	137,398	134,864
Cash at bank		761,243	15,375	776,618	815,630
		898,641	15,375	914,016	950,494
CREDITORS					
Amounts falling due within one year	14	(117,958)	-	(117,958)	(41,637)
NET CURRENT ASSETS		780,683	15,375	796,058	908,857
TOTAL ASSETS LESS CURRENT LIABILITIES		781,781	15,375	797,156	911,055
NET ASSETS		781,781	15,375	797,156	911,055
FUNDS	15				
Unrestricted funds				781,781	868,296
Restricted funds				15,375	42,759
TOTAL FUNDS				797,156	911,055

The financial statements were approved by the Board of Trustees and authorised for issue on ..... and were signed on its behalf by:

10/16/2026

.....
C A Romero - Trustee

The notes form part of these financial statements

1. ACCOUNTING POLICIES

Basis of preparing the financial statements
The financial statements of the charity, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Charities Act 2011. The financial statements have been prepared under the historical cost convention.

The financial statements are prepared in Sterling, which is the functional currency of the charity.

All the assets, liabilities, and activities of the International Society of Hypertension (unincorporated charity registration number 1122135) transferred from that charity to the CIO uninterrupted as at 23 December 2024. The financial statements have been prepared using merger accounting. Comparative figures shown relate to combination of the old charity and the CIO.

Going concern
At the time of approving the financial statements, the Trustees have a reasonable expectation that the International Society of Hypertension has adequate resources to continue in operational existence for the foreseeable future. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

Income
All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Cash donations are recognised on receipt. Other donations are recognised once the International Society of Hypertension has been notified of the donation, unless performance conditions require deferral of the sum.

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the bank.

Expenditure
Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Fixtures and fittings	- 33% on cost
Computer equipment	- 33% on cost

Taxation
The charity is exempt from tax on its charitable activities.

Fund accounting
Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

continued...

1. ACCOUNTING POLICIES - continued

Foreign currencies
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Pension costs and other post-retirement benefits
The charity operates a defined contribution pension scheme. Contributions payable to the charity's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

Financial instruments
The International Society of Hypertension only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors.

Debt instruments that are payable or receivable within one year, typically trade debtors and creditors, are measured, initially and subsequently, at the undiscounted amount of the cash or other consideration, expected to be paid or received.

Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in profit and loss.

For financial assets measured at amortised cost, the impairment loss is measured as the loss between an asset's carrying value and the present value of future cashflow discounted at the asset's original effective interest rate.

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

2. CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY

In application of the International Society of Hypertension's accounting policies, the Trustees are required to make judgements, estimates and assumptions of the carrying amount of assets and liabilities that are not readily apparent from other sources. the estimates and associated assumptions are based on historical experience and other factors considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of revision and future period where the revision effects both current and future periods.

3. CHARITABLE ACTIVITIES

	2025	2024
	£	£
Corporate membership fees	76,135	61,817
Membership fees	14,118	15,852
Biennial meeting	-	19,936
Journal of Hypertension Royalties	105,235	104,830
Patient guideline initiative	-	86,684
ISH branded endorsements	22,556	22,882
	218,044	312,001

continued...

4. INVESTMENT INCOME

	2025	2024
	£	£
Deposit account interest	8,423	4,845

5. RAISING FUNDS

Raising donations and legacies

	2025	2024
	£	£
Consultancy (fund raising)	24,866	-
Fund raising costs	281	-
Support costs	143,500	155,382
	168,647	155,382

6. CHARITABLE ACTIVITIES COSTS

	Direct Costs	Grant funding of activities	Support costs (see note 7)	Totals
	£	£	£	£
Charitable activities	95,353	20,972	31,489	147,814

Initiative and meeting expenses are shown in full to provide the fullest possible information. During the year income of £nil (2024: £19,936) was received from donors and sponsors to defray those costs.

7. SUPPORT COSTS

	Management	Other	Governance costs	Totals
	£	£	£	£
Raising donations and legacies	136,510	-	6,990	143,500
Charitable activities	-	31,489	-	31,489
	136,510	31,489	6,990	174,989

Governance costs includes payments to the firm that employs the independent examiner of £6,040 (2024: £5,080) for independent examination fees and for the preparation of the annual financial statements to comply with the Charities Acts, and £950 (2024: £1,711) for other services.

8. TRUSTEES' REMUNERATION AND BENEFITS

None of the Trustees (or any persons connected with them) received any remuneration or benefits from the International Society of Hypertension during the year.

continued...

9. EMPLOYEES

There was one (2024: one) employee during the year.

10. EXCEPTIONAL ITEMS

Exceptional items include foreign exchange loss in the sum of £23,905 (2024: £15.958). These include unrealised gains and losses arising as a result of revaluing foreign exchange balances using the rate prevailing at the end of the financial year.

11. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	Unrestricted fund £	Restricted fund £	Total funds £
INCOME AND ENDOWMENTS FROM			
Donations and legacies	1,162	-	1,162
Other trading activities	225,317	86,684	312,001
Investment income	4,845	-	4,845
Total	231,324	86,684	318,008
EXPENDITURE ON			
Raising funds	169,666	1,674	171,340
Charitable activities			
Charitable activities	121,312	42,251	163,563
Total	290,978	43,925	334,903
NET INCOME/(EXPENDITURE)	(59,654)	42,759	(16,895)
RECONCILIATION OF FUNDS			
Total funds brought forward	927,950	-	927,950
TOTAL FUNDS CARRIED FORWARD	868,296	42,759	911,055

12. TANGIBLE FIXED ASSETS

	Fixtures and fittings £	Computer equipment £	Totals £
COST			
At 1 January 2025 and 31 December 2025	799	2,499	3,298
DEPRECIATION			
At 1 January 2025	267	833	1,100
Charge for year	267	833	1,100
At 31 December 2025	534	1,666	2,200
NET BOOK VALUE			
At 31 December 2025	265	833	1,098
At 31 December 2024	532	1,666	2,198

continued...

13. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2025	2024
	£	£
Trade debtors	-	5,910
Other debtors	21,229	21,229
Social security & other taxes	-	39
Accrued income	111,039	105,143
Prepayments	5,130	2,543
	137,398	134,864

14. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2025	2024
	£	£
Trade creditors	26,400	21,640
Other creditors	2,513	4,210
Deferred income	83,405	10,787
Accrued expenses	5,640	5,000
	117,958	41,637

15. MOVEMENT IN FUNDS

	At 1.1.25	Net movement in funds	At 31.12.25
	£	£	£
Unrestricted funds			
General fund	868,296	(86,515)	781,781
Restricted funds			
Patient Guideline Initiative	42,759	(27,384)	15,375
TOTAL FUNDS	911,055	(113,899)	797,156

Net movement in funds, included in the above are as follows:

	Incoming resources	Resources expended	Movement in funds
	£	£	£
Unrestricted funds			
General fund	226,467	(312,982)	(86,515)
Restricted funds			
Patient Guideline Initiative	-	(27,384)	(27,384)
TOTAL FUNDS	226,467	(340,366)	(113,899)

continued...

15. MOVEMENT IN FUNDS - continued

Comparatives for movement in funds

	At 1.1.24	Net movement in funds	At 31.12.24
	£	£	£
Unrestricted fund	927,950	(59,654)	868,296
Restricted fund			
Patient Guideline Initiative	-	42,759	42,759
TOTAL FUNDS	927,950	(16,895)	911,055

Comparative net movement in funds included in the above are as follows:

	Incoming resources	Resources expended	Movement in funds
	£	£	£
Unrestricted fund	231,324	(290,978)	(59,654)
Restricted fund			
Patient Guideline Initiative	86,684	(43,925)	42,759
TOTAL FUNDS	318,008	(334,903)	(16,895)

A current year 12 months and prior year 12 months combined position is as follows:

	At 1.1.24	Net movement in funds	At 31.12.25
	£	£	£
Unrestricted fund	927,950	(146,169)	781,781
Restricted fund			
Patient Guideline Initiative	-	15,375	15,375
TOTAL FUNDS	927,950	(130,794)	797,156

Net movement in funds included in the above are as follows:

	Incoming resources	Resources expended	Movement in funds
	£	£	£
Unrestricted fund	457,791	(603,960)	(146,169)
Restricted fund			
Patient Guideline Initiative	86,684	(71,309)	15,375
TOTAL FUNDS	545,787	(675,269)	(130,794)

continued...

15. MOVEMENT IN FUNDS - continued

Purpose of restricted fund
The Patient Guideline Initiative Fund was started by a grant of £86,684 given to the charity to create a new flagship global programme "ISH Empower". This is a patient centred guideline to empower patients to better detect, monitor and control their blood pressure.
The restricted fund was transferred to the CIO and any restrictions in place preserved.

16. RELATED PARTY TRANSACTIONS

No key management personnel received any remuneration in the current or prior year.

During the year the International Society of Hypertension entered into the following transactions with some of its trustees, in respect of travel and accommodation expenses reimbursed in the sum of £55,047 (2024: £101,662). The number of trustees so reimbursed was 13 (2024: 11).